LivaNova Raises 2026 Guidance After 10.8% Revenue Jump, $95M Tax Windfall
LIVN has more than doubled off its 52-week low of $41.133.
Summary
LivaNova delivered a strong Q2 with revenue of $390.6M, up 10.8% reported, beating estimates, driven by Cardiopulmonary and Neuromodulation growth. Adjusted diluted EPS came in at $1.26. The company raised its full-year 2026 constant-currency revenue growth guidance to 8-9% and adjusted diluted EPS to $4.30-$4.40, reflecting confidence in core business momentum. A $95.4M discrete tax benefit from an Italian ruling significantly boosts GAAP earnings. The new long-term supply agreement with Thermo Fisher addresses a critical oxygenator component bottleneck, supporting future output. These results follow the June OSPREY study data and shareholder approval of share issuance authority, reinforcing the strategic plan's execution.
At the time of this announcement, LIVN was trading at $87.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $41.13 to $85.76. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.